Business
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control armElraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysisClinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rateElraglusib/GnP combination arm demonstrated a favorable risk-benefit profileTopline dataset to be presented in an oral presentation at
About this update from Actuate Therapeutics, Inc.
[{"type":"image","alt":"Actuate Therapeutics","displaySize":"","headline":null,"caption":"Actuate Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/8600bbc6448d867dc281bd537c05e09e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/33fX_k368HBbxSS0OT6lrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8600bbc6448d867dc281bd537c05e09e","width":300,"height":117}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysis","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rate","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Elraglusib/GnP combination arm demonstrated a favorable risk-benefit profile","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting ","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Company plans to work with regulators to expeditiously bring elraglusib to commercialization","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":624,"olType":false},{"type":"text","content":"CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results from its ongoing Phase 2 (Actuate-1801 Part 3B) trial in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).","length":641,"tagName":"p"},{"type":"text","content":"The topline results, which demonst...